I think this news shows you need to make sure your studies are a) well designed b) you don't make suspicious moves to secondary endpoints and bring in new investigators during the study and c) if you do all of those bad things-don't try and hide it. Though the study didn't show that Vytorin was superior or inferior-one always has to ask "What are they hiding?" and the effects of that decision are starting play out. The American College of Cardiology is meeting in March, and will release a statement on the trial then. But, will it be too late?
Saturday, February 23, 2008
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment